Horm Metab Res 2022; 54(09): 620-624
DOI: 10.1055/a-1880-1264
Original Article: Endocrine Care

Early Clinical, Biochemical and Radiological Features in Obese and Non-Obese Young Women with Polycystic Ovarian Syndrome: A Comparative Study

1   Obstetrics and Gynecology, All India Institute of Medical Sciences – Bibinagar, Hyderabad, India
,
Himani Agarwal
2   Obstetrics and Gynecology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Ambala, India
› Author Affiliations

Abstract

Polycystic ovarian syndrome (PCOS) is a heterogenous condition accounting for serious health complications. The present study was conducted to assess the early clinical, biochemical, and radiological features in obese, non-obese young women with PCOS as compared to non-PCOS women. The study was conducted on 120 young women (18–22 years) with 80 having features of PCOS [40 obese (BMI≥25 kg/m2) and 40 non-obese (BMI<25 kg/m2) PCOS] as cases and 40 without PCOS as controls in a rural tertiary care center of Northern India over one year (2017–2018). After enrolment of cases and control, the anthropometric measurements, early clinical symptoms, and biochemical and ultrasonographic features were compared between the groups. Statistical analysis was done using SPSS software version 22.0 (p-value<0.05). A significant difference in anthropometric measurements were observed between obese and non-obese PCOS cases. Clinical features like acne, acanthosis nigricans, and hirsutism were more prevalent in obese PCOS as compared to non-obese and controls. On ultrasound, PCOS cases had a significantly increased number of peripherally arranged ovarian follicles, and ovarian volume. The LH: FSH ratio was significantly higher in cases as compared to controls. The levels of serum LH (10.04±1.60 vs. 8.93±2.40 mIU/ml) and total testosterone (2.71±0.39 vs. 2.21±0.39 pg/ml) were higher in obese PCOS as compared to non-obese PCOS cases. In conclusion, clinical, biochemical, and radiological features can be used in the early diagnosis of PCOS. Obesity is an independent risk factor for PCOS and is associated with an increased risk of complications.



Publication History

Received: 05 April 2022

Accepted after revision: 10 June 2022

Article published online:
20 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Sharma M, Khapre M, Saxena V. et al. Polycystic ovary syndrome among Indian adolescent girls – a systematic review and metanalysis. Nepal J Epidemiol 2021; 11: 1063-1075
  • 2 Rajkumari P, Sahoo J, Sujata P. et al. Awareness about PCOS and the likelihood of its symptoms in adolescent girls in a semi-urban set-up: a cross sectional study. J Med Sci Clin Res 2016; 4: 12264-12269
  • 3 Ding T, Hardiman PJ, Petersen I. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget 2017; 8: 96351-96358
  • 4 Naz MSG, Tehrani FR, Majd HA. et al. The prevalence of polycystic ovary syndrome in adolescents: a systematic review and meta-analysis. Int J Reprod Biomed 2019; 17: 533-542
  • 5 Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc 2019; 3: 1545-1573
  • 6 Alsadi B. Clinical features of PCOS. In: Wang Z. (ed). Polycystic Ovarian Syndrome [Internet]. London: IntechOpen [cited 2022 Mar 20]; Available from https://www.intechopen.com/chapters/70216 DOI: 10.5772/intechopen.89961 2019
  • 7 Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 2016; 37: 467-520
  • 8 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47
  • 9 Azziz R, Carmina E, Dewailly D. et al. Androgen excess society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245
  • 10 Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1-13
  • 11 Weir CB, Jan A. BMI classification percentile and cut off points. [Updated 2021 Jun 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Available from https://www.ncbi.nlm.nih.gov/books/NBK541070/ 2022
  • 12 Hatch R, Rosenfield RL, Kim MH. et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; c140: c815-c830
  • 13 Barber TM, Hanson P, Weickert MO. et al. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health 2019; 13: 1179558119874042
  • 14 Barber TM, Franks H. Obesity and polycystic ovarian syndrome. Clin Endocrinol 2021; 95: 531-541
  • 15 Demir B, Pasa S, Demir S. et al. Hirsutism score and the severity of hyperandrogenism associated with polycystic ovary syndrome in the southeastern region of Turkey. J Int Med Res 2011; 39: 1529-1535
  • 16 Gupta N, Radhakrishnan G, Madhu SV. et al. Comparison of metabolic and endocrinal parameters in obese and nonobese women of polycystic ovarian syndrome with normal controls. Fertil Sci Res 2015; 2: 19-23
  • 17 Akshaya S, Bhattacharya R. Comparative study of clinical profile of lean and obese polycystic ovary syndrome women. Int J Reprod Contracept Obstet Gynecol 2016; 5: 2530-2533
  • 18 Glintborg D, Petersen MH, Ravn P. et al. Comparison of regional fat mass measurement by whole-body DXA scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls. Acta Obstet Gynecol Scand 2016; 95: 1235-1243
  • 19 Gill H, Tiwari P, Dabadghao P. Prevalence of polycystic ovary syndrome in young women from North India: a community-based study. Indian J Endocrinol Metab 2012; 16 (Suppl. 02) S389-S392 Erratum in: Indian J Endocrinol Metab 2013; 17: 162
  • 20 Neubronner SA, Indran IR, Chan YH. et al. Effect of body mass index (BMI) on phenotypic features of polycystic ovary syndrome (PCOS) in Singapore women: a prospective cross-sectional study. BMC Womens Health 2021; 21: 135
  • 21 Ahmadi A, Akbarzadeh M, Mohammadi F. et al. Anthropometric characteristics and dietary pattern of women with polycystic ovary syndrome. Indian J Endocrinol Metab 2013; 17: 672-676
  • 22 Majumdar A, Singh TA. Comparison of clinical features and health manifestations in lean vs. obese Indian women with polycystic ovarian syndrome. J Hum Reprod Sci 2009; 2: 12-17
  • 23 Sachdeva G, Gainder S, Suri V. et al. Obese and non-obese polycystic ovarian syndrome: comparison of clinical, metabolic, hormonal parameters, and their differential response to clomiphene. Indian J Endocrinol Metab 2019; 23: 257-262
  • 24 Shivaprakas G, Basu A, Kamath A. et al. Acanthosis nigricansin PCOS Patients and its relation with type 2 diabetes mellitus and body mass at a tertiary care hospital in Southern India. J Clin Diagn Res 2013; 7: 317-319
  • 25 Gowri BV, Chandravathi PL, Sindhu PS. et al. Correlation of skin changes with hormonal changes in polycystic ovarian syndrome: a cross-sectional clinical study. Indian J Dermatol 2015; 60: 419
  • 26 Gholinezhad M, Gholsorkhtabaramiri M, Esmaeilzadeh S. et al. Insulin resistance and adverse metabolic profile in overweight/obese and normal weight of young women with polycystic ovary syndrome. Caspian J Intern Med 2018; 9: 260-267
  • 27 Gharakhani M, Neghab N, Farimani M. Is reducing ovarian volume in polycystic ovarian syndrome patients after administration of metformin associated with improving cardiovascular risk factors?. Int J Fertil Steril 2011; 5: 90-95
  • 28 Ahmed AA, Moselhy SS, Kumosani TA. et al. Ultrasonographic and biochemical assessments as early prediction of polycystic ovarian syndrome in obese women. Afri Health Sci 2020; 20: 676-681
  • 29 Agrawal A, Yonati V, Bhandari G. et al. Evaluation of PCOS in obese and non-obese patients using transvaginal ovarian and uterine artery color doppler. GJRA 2021; 10: 40-42
  • 30 Moran C, Renteria JL, Moran S. et al. Obesity differentially affects serum levels of androstenedione and testosterone in polycystic ovary syndrome. Fertil Steril 2008; 90: 2310-2317
  • 31 Saadia Z. Follicle stimulating hormone (LH: FSH) ratio in polycystic ovary syndrome (PCOS) – obese vs. non-obese women. Med Arch 2020; 74: 289-293
  • 32 Panidis D, Farmakiotis D, Rousso D. et al. Serum luteinizing hormone levels are markedly increased and significantly correlated with delta 4-androstenedione levels in lean women with polycystic ovary syndrome. Fertil Steril 2005; 84: 538-540